BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 7458646)

  • 1. [Clinical and therapeutic evaluation of a new antilipemic substance].
    de Aguiar Magano L
    Arch Sci Med (Torino); 1980; 137(1):131-9. PubMed ID: 7458646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correction of hyperdyslipidemia using polyene-structure substances. Controlled clinical trial].
    Pagliano FM
    Arch Sci Med (Torino); 1979; 136(2):303-8. PubMed ID: 391176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of a new synthetic compound (3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate: I.612) on plasma lipids in patients with type IIa, IIb and IV hyperdyslipidemia].
    Bucalossi A; Buzzelli G; D'Alessandro A
    Clin Ter; 1979 Apr; 89(2):127-49. PubMed ID: 226307
    [No Abstract]   [Full Text] [Related]  

  • 5. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
    Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
    Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlorophenoxyisobutyric acid derivatives and apolipoprotein B metabolism.
    Shepherd J; Packard CJ
    Monogr Atheroscler; 1985; 13():85-91. PubMed ID: 4088282
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
    Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clofibrate controlled trial of gemfibrozil in the treatment of hyperlipidaemias.
    Tuomilehto J; Salonen J; Kuuisto P; Virtamo J; Manninen V; Mälkönen M
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):38-40. PubMed ID: 798195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical effects and tolerance of etofylline clofibrate].
    Ziegler WJ; Metz G; Specker M
    Arzneimittelforschung; 1980; 30(11b):2053-8. PubMed ID: 7194059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].
    Sterner W; Chibanguza G; Metz G
    Arzneimittelforschung; 1980; 30(11b):2038-41. PubMed ID: 7194056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term effect of alufibrate in various types of hyperlipidaemia (author's transl)].
    Stähelin HB; Hartmann G
    Dtsch Med Wochenschr; 1974 Jun; 99(26):1392-4 passim. PubMed ID: 4601124
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparative studies on the reduction of lipids using clofibric acid and clofibrate in hyperlipoproteinemias].
    Schwartzkopff W; Hoffmann H; Kästner W
    Med Welt; 1975 Dec; 26(51):2308-15. PubMed ID: 177837
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current trends in the therapy of arteriosclerotic disease].
    Toscano S
    G Clin Med; 1974 Jan; 55(1):27-39. PubMed ID: 4369524
    [No Abstract]   [Full Text] [Related]  

  • 16. Clofibrate treatment of hyperlipidemia in chronic renal failure.
    di Giulio S; Boulu R; Drüeke T; Nicolaĭ A; Zingraff J; Crosnier J
    Clin Nephrol; 1977 Dec; 8(6):504-9. PubMed ID: 598055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response effect of single and combined clofibrate (Atromidin) and niceritrol (Perycit) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia.
    Olsson AG; Orö L; Rössner S
    Atherosclerosis; 1975; 22(1):91-101. PubMed ID: 1098680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New drug combination for medical management of hyperlipemia: clinical study].
    Fischer M; Falkensammer C
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):585-9. PubMed ID: 340391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experimentation of clofibride. Apropos of 40 cases].
    Warembourg H; Jaillard J
    Lille Med; 1973 Dec; 18(10 Suppl 5):suppl 5:1292-6. PubMed ID: 4802928
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man.
    Goodman DS; Noble RP; Dell RB
    J Clin Invest; 1973 Oct; 52(10):2646-55. PubMed ID: 4729058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.